<SEC-DOCUMENT>0001193125-25-250674.txt : 20251027
<SEC-HEADER>0001193125-25-250674.hdr.sgml : 20251027
<ACCEPTANCE-DATETIME>20251027070013
ACCESSION NUMBER:		0001193125-25-250674
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20251026
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251027
DATE AS OF CHANGE:		20251027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FATE THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001434316
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				651311552
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36076
		FILM NUMBER:		251417419

	BUSINESS ADDRESS:	
		STREET 1:		12278 SCRIPPS SUMMIT DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92131
		BUSINESS PHONE:		858.875.1803

	MAIL ADDRESS:	
		STREET 1:		12278 SCRIPPS SUMMIT DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92131
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d36426d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:fate="http://www.fatetherapeutics.com/20251026" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2025-10-26_to_2025-10-26">FATE THERAPEUTICS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-289">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-10-26_to_2025-10-26">0001434316</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="fate-20251026.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-10-26_to_2025-10-26"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-10-26</xbrli:startDate> <xbrli:endDate>2025-10-26</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-300">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-10-26_to_2025-10-26" format="ixt:datemonthdayyearen" id="ixv-301">October 26, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">FATE THERAPEUTICS, INC.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-10-26_to_2025-10-26" format="ixt-sec:stateprovnameen" id="ixv-302">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-303">001-36076</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-304">65-1311552</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-305">12278 Scripps Summit Drive</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-306">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-10-26_to_2025-10-26" format="ixt-sec:stateprovnameen" id="ixv-307">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-308">92131</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-309">858</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-310">875-1800</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-10-26_to_2025-10-26" format="ixt-sec:boolballotbox" id="ixv-311">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-10-26_to_2025-10-26" format="ixt-sec:boolballotbox" id="ixv-312">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-10-26_to_2025-10-26" format="ixt-sec:boolballotbox" id="ixv-313">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-10-26_to_2025-10-26" format="ixt-sec:boolballotbox" id="ixv-314">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-315">Common Stock, $0.001 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-316">FATE</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-10-26_to_2025-10-26" format="ixt-sec:exchnameen" id="ixv-317">Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-10-26_to_2025-10-26" format="ixt-sec:boolballotbox" id="ixv-318">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;7.01 Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;26, 2025, Fate Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release&#160;(i) announcing that 10 patients with treatment-refractory, <span style="white-space:nowrap"><span style="white-space:nowrap">moderate-to-severe</span></span> systemic lupus erythematosus (&#8220;SLE&#8221;) were treated with a single dose of FT819, the Company&#8217;s <span style="white-space:nowrap"><span style="white-space:nowrap">off-the-shelf,</span></span> CD19-targeted 1XX chimeric antigen receptor (&#8220;CAR&#8221;) <span style="white-space:nowrap">T-cell</span> product candidate as of a data cut-off date of September&#160;25, 2025, and (ii)&#160;highlighting new and updated data (including, without limitation, translational data) as of the data cut-off date from the first 10 patients dosed with FT819 in a Phase 1 clinical trial for the treatment of <span style="white-space:nowrap"><span style="white-space:nowrap">moderate-to-severe</span></span> SLE at the American College of Rheumatology (&#8220;ACR&#8221;) Convergence 2025 in Chicago. The press release also highlighted that the Company (i)&#160;has initiated independent dose-expansion cohorts in anti-neutrophilic cytoplasmic antibody-associated vasculitis (&#8220;AAV&#8221;), idiopathic inflammatory myositis (&#8220;IIM&#8221;), and systemic sclerosis (&#8220;SSc&#8221;), and (ii)&#160;is actively engaged under its Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) to align on a registrational study design with the goal of initiating a pivotal study in 2026. The press release is furnished as Exhibit 99.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company posted links to the ACR Convergence 2025 abstracts in connection with its FT819 programs on its website. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in Item 7.01 of this Current Report on <span style="white-space:nowrap">Form&#160;8-K,&#160;including</span> Exhibit 99.1 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01 Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">FT819 iPSC-derived CAR <span style="white-space:nowrap">T-cell</span> Program </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;26, 2025, the Company (i)&#160;announced that 10 patients with treatment-refractory, <span style="white-space:nowrap"><span style="white-space:nowrap">moderate-to-severe</span></span> SLE were treated with a single dose of FT819, the Company&#8217;s <span style="white-space:nowrap"><span style="white-space:nowrap">off-the-shelf,</span></span> CD19-targeted CAR <span style="white-space:nowrap">T-cell</span> product candidate as of a data cut-off date of September 25, 2025, and (ii)&#160;highlighted new and updated data (including, without limitation, translational data) as of the data cut-off date at the ACR Convergence 2025 from its Phase 1 clinical trial of FT819 for the treatment of <span style="white-space:nowrap"><span style="white-space:nowrap">moderate-to-severe</span></span> SLE, which data underscored the unique ability of FT819 to remodel the <span style="white-space:nowrap">B-cell</span> repertoire toward a more na&#239;ve and less pathogenic state without the need for intensive conditioning chemotherapy. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study is designed to evaluate the safety, pharmacokinetics, and activity of a single dose of FT819 administered to patients with active refractory lupus with either (i)&#160;a less-intensive conditioning regimen (Regimen A; fludarabine (flu)-free conditioning consisting of either cyclophosphamide alone or bendamustine alone), or (ii)&#160;a conditioning-free regimen to patients on <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> maintenance therapy (Regimen B). The Company announced key insights from the study with respect to 10 patients (8 on Regimen A, 2 on Regimen B) who have been treated with FT819 as of a data <span style="white-space:nowrap">cut-off</span> date of September&#160;25, 2025. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The data showed that, in patients treated with less-intensive conditioning chemotherapy, rapid and sustained CD19+ B cell depletion was observed, positively correlating with dose escalation. Upon return of the B cell compartment, na&#239;ve B cell emergence beyond baseline levels was observed, suggestive of an immune reset and correlative to reduction in disease burden. Further, in patients treated without conditioning chemotherapy, a meaningful reduction in CD19+ B cells was also observed, alongside reduction in expanded <span style="white-space:nowrap">B-cell</span> clones and remodeling of the <span style="white-space:nowrap">B-cell</span> compartment that correlated with improvement in disease activity scores. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;contains</span> forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. These forward-looking statements include, but are not limited to, express or implied statements regarding the Company&#8217;s beliefs and expectations regarding: the advancement of and plans related to the Company&#8217;s product candidates, clinical studies and preclinical research and development programs, the safety and therapeutic potential of the Company&#8217;s product candidates, including FT819, the Company&#8217;s progress, plans and timelines for the clinical investigation of its product candidates, including the Company&#8217;s plans to complete Investigational New Drug (IND)-enabling studies and to submit IND applications for its product candidates, the initiation and continuation of enrollment in the Company&#8217;s clinical trials, the initiation of additional clinical trials, including in new indications, and additional dose cohorts in ongoing clinical trials of the Company&#8217;s product candidates, the availability of data from the Company&#8217;s clinical trials and the Company&#8217;s plans to provide updates on its clinical trials, the therapeutic and market potential of the Company&#8217;s research and development programs and product candidates, and the Company&#8217;s clinical and product development strategy. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These and any other forward-looking statements in this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;are</span> based on management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that could cause our actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company&#8217;s product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company&#8217;s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company&#8217;s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company&#8217;s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company&#8217;s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company&#8217;s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company&#8217;s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company&#8217;s periodic filings with the Securities and Exchange Commission, including but not limited to the Company&#8217;s most recently filed periodic report, and from time to time in the Company&#8217;s press releases and other investor communications. Fate Therapeutics is providing the information in this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;as</span> of this date and does not undertake any obligation to update any forward-looking statements contained in this report as a result of new information, future events or otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(d) Exhibits. </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit<br/>No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d36426dex991.htm">Press Release dated October&#160;26, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">FATE THERAPEUTICS, INC.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:&#8195; October&#160;27, 2025</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bahram Valamehr</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Bahram Valamehr, Ph.D., M.B.A. <br/>President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d36426dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with
Systemic Lupus Erythematosus Treated with FT819 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Off-the-Shelf</FONT></FONT> CAR <FONT STYLE="white-space:nowrap">T-Cell</FONT> Therapy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>As of a September&nbsp;25, 2025 data <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cut-off-date,</FONT></FONT> 10
patients with treatment-refractory, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning
chemotherapy </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Favorable safety profile with no dose-limiting toxicities supports plan to enable
<FONT STYLE="white-space:nowrap">same-day</FONT> discharge post FT819 treatment broadening patient accessibility </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>All patients
surpassing a <FONT STYLE="white-space:nowrap">3-month</FONT> post-treatment time point (n=5) showed significant reductions in the SLE Disease Activity Index <FONT STYLE="white-space:nowrap">(SLEDAI-2K)</FONT> score and Physician&#8217;s Global
Assessment (PGA) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>SLE patients with lupus nephritis (LN) surpassing a <FONT STYLE="white-space:nowrap">3-month</FONT> post-treatment
time point (n=2) achieved complete renal response (CRR) at 6 months; first patient continues in drug-free Definition of Remission in SLE (DORIS) at 15 months <FONT STYLE="white-space:nowrap">follow-up</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cumulative clinical dataset provides clear evidence for rapid CD19+ B cell depletion and immune remodeling toward a na&iuml;ve and less
pathogenic <FONT STYLE="white-space:nowrap">B-cell</FONT> repertoire </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>San Diego &#8212; October</B><B></B><B>&nbsp;26, 2025</B> &#8212; Fate
Therapeutics, Inc<I>.</I> (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> pipeline of induced pluripotent stem cell
(iPSC)-derived <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> cellular immunotherapies to patients for broad accessibility, today announced new and updated data from the first 10 patients dosed with
FT819 in a Phase 1 clinical trial for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> systemic lupus erythematosus (SLE) at the American College of Rheumatology (ACR) Convergence
2025 in Chicago. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;This promising initial clinical data demonstrates that FT819 can deliver transformative outcomes in patients with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> SLE, particularly with reduced or no conditioning chemotherapy,&#8221; said Bob Valamehr, Ph.D., M.B.A., President and Chief Executive Officer of Fate
Therapeutics. &#8220;Having shown meaningful and durable clinical activity, a safety profile enabling plans for <FONT STYLE="white-space:nowrap">same-day</FONT> discharge, and robust enrollment from the first four enrolling clinical sites, we expect
accelerated patient enrollment as additional sites join the study. With many more sites now participating, we aim to promptly complete our Phase 1 trial. In addition, under our RMAT designation, we continue to engage with the FDA on a registrational
study design with the goal of initiating a pivotal study next year. We are making great progress on our mission to make FT819 available <FONT STYLE="white-space:nowrap">on-demand,</FONT> in a true <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> and cost-effective manner, with the potential to help patients suffering with SLE and other autoimmune diseases.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New and Updated Clinical Data Summary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is
currently conducting a multi-center, Phase 1 clinical trial of FT819, its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf,</FONT></FONT> CD19-targeted, 1XX CAR <FONT STYLE="white-space:nowrap">T-cell</FONT> product
candidate, for the treatment of patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> SLE, including lupus nephritis and extrarenal lupus (NCT06308978). The study is designed to evaluate the
safety, pharmacokinetics, and activity of a single dose of FT819 administered to patients with active refractory lupus with either (i)&nbsp;a less-intensive conditioning regimen (Regimen A; fludarabine (flu)-free conditioning consisting of either
cyclophosphamide alone or bendamustine alone), or (ii)&nbsp;a conditioning-free regimen to patients on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> maintenance therapy (Regimen B). As of the data <FONT
STYLE="white-space:nowrap">cut-off</FONT> date of September&nbsp;25, 2025, 10 patients (8 on Regimen A, 2 on Regimen B) have been treated with FT819, providing the following key insights: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Less-intensive Conditioning Regimen </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Active Lupus Nephritis</I></B>. Five patients with active refractory lupus nephritis (prior therapies range
between 7 and 8, with all patients having received prior <FONT STYLE="white-space:nowrap">B-cell</FONT> targeted therapy; baseline SLE Disease Activity Index <FONT STYLE="white-space:nowrap">(SLEDAI-2K)</FONT> ranging between 8 and 20) were treated
with a single dose of FT819 in the less-intensive conditioning regimen. As of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date, two patients who were treated at dose level 1 (DL1, 360&nbsp;million cells) had surpassed the <FONT
STYLE="white-space:nowrap">3-month</FONT> evaluation timepoint and exhibited significant reductions of 16 and 12 points, respectively, in <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> from baseline and importantly, Urine <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Protein-to-Creatinine</FONT></FONT> ratio (UPCr) reduction to <U>&lt;</U> 0.5 mg/mg at 6 months. The patient who exhibited a 16 point <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT>
reduction discontinued steroids and achieved DORIS (definition of remission in SLE) and complete renal response (CRR) at 6 months and remains in steroid-free DORIS and CRR at the <FONT STYLE="white-space:nowrap">15-month</FONT> <FONT
STYLE="white-space:nowrap">follow-up.</FONT> The second patient exhibited a 12 point reduction in <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> and achieved CRR at 6 months; however, this patient subsequently experienced a disease flare and at
the <FONT STYLE="white-space:nowrap">12-month</FONT> evaluation timepoint is under consideration for retreatment with FT819. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Extrarenal Lupus. </I></B>Three patients with active <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> extrarenal lupus (prior therapies ranging between 3 and 10; baseline <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> ranging between 14 and 18) were treated with a single dose of FT819 in
the less-intensive conditioning regimen. As of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date, two patients had surpassed the <FONT STYLE="white-space:nowrap">3-month</FONT> evaluation timepoint. Both patients were treated at dose
level 2 (DL2, 900&nbsp;million cells). The first patient exhibited a significant reduction of <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> from 18 to 10 at <FONT STYLE="white-space:nowrap">one-month</FONT> post-treatment; however, this patient
was restarted on anifrolumab two months after treatment with FT819, which the patient had been on for the previous 3 years. <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> score and PGA continued to improve thereafter, and DORIS was achieved at 6
months post-treatment with FT819. Notably, these results were not previously achieved for this patient with treatment with combination therapy that included anifrolumab prior to starting treatment with FT819. The second patient also demonstrated
significant reduction in <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> score to 6 from a baseline of 16, a meaningful reduction of PGA to 0.4 from a baseline of 2.2 and dramatically improved FACIT score at the
<FONT STYLE="white-space:nowrap">3-month</FONT> evaluation timepoint. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Conditioning-free Regimen </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I><FONT STYLE="white-space:nowrap">Add-on</FONT> to Maintenance Therapy</I></B>. Two patients were treated
with a single dose of FT819 at 360&nbsp;million cells in the conditioning-free regimen as an <FONT STYLE="white-space:nowrap">add-on</FONT> to mycophenolate mofetil maintenance therapy (one patient with extrarenal lupus with prior therapies = 5,
baseline <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> = 8; and a second patient with lupus nephritis prior therapies = 8, baseline <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> = 17). As of the data
<FONT STYLE="white-space:nowrap">cut-off</FONT> date, the patient with extrarenal lupus had surpassed the <FONT STYLE="white-space:nowrap">3-month</FONT> evaluation timepoint and achieved low lupus disease activity state (LLDAS) by 3 months from
FT819 administration, which was maintained at the most recent <FONT STYLE="white-space:nowrap">follow-up</FONT> at 9 months. The patient also experienced meaningful reductions in <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> to 2 from 8 at
baseline and in PGA to 0.5 from 2 at baseline, with steroids that were tapered to less than 5 mg / day. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Safety
</U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In more than 60 patients treated with FT819 across autoimmune disease and oncology, favorable safety profile
continues to be observed with low incidence of <FONT STYLE="white-space:nowrap">low-grade</FONT> cytokine release syndrome (CRS), no events of immune effector cell-associated neurotoxicity (ICANS), and no events of graft-versus-host disease (GvHD).
Specifically, in the 8 safety-evaluable patients treated with FT819 for SLE with at least one month <FONT STYLE="white-space:nowrap">follow-up</FONT> as of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there have been no events of ICANS, no events of GvHD, and 3 patients who experienced <FONT
STYLE="white-space:nowrap">low-grade</FONT> CRS (Grade 2 in maximum severity in 1 patient, Grade 1 in maximum severity in 2 patients); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no dose-limiting toxicities were observed in any patient; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all patients were discharged following a short-duration of hospitalization post infusion of FT819, supporting the
potential for outpatient administration and <FONT STYLE="white-space:nowrap">same-day</FONT> discharge. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Translational </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In patients treated with less-intensive conditioning chemotherapy, rapid and sustained CD19+ B cell depletion was
observed, positively correlating with dose escalation. Upon return of the B cell compartment, na&iuml;ve B cell emergence beyond baseline levels was observed, suggestive of an immune reset and correlative to reduction in disease burden.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In patients treated without conditioning chemotherapy, a meaningful reduction in CD19+ B cells was also observed,
alongside reduction in expanded <FONT STYLE="white-space:nowrap">B-cell</FONT> clones and remodeling of the B cell compartment that correlated with improvement in disease activity scores. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">These observations underscore the unique ability of FT819 to remodel the
<FONT STYLE="white-space:nowrap">B-cell</FONT> repertoire toward a more na&iuml;ve and less pathogenic state without the need for intensive conditioning chemotherapy. The mechanistic remodeling of the B cell compartment supports immune restoration
as a driver of clinical remission, reinforcing transformative potential of FT819 in autoimmune disease treatment. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Program Expansion and Outlook </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has initiated independent dose-expansion cohorts in anti-neutrophilic cytoplasmic antibody-associated vasculitis (AAV), idiopathic inflammatory
myositis (IIM), and systemic sclerosis (SSc). In addition, the Company is actively engaged under its Regenerative Medicine Advanced Therapy (RMAT) designation with the U.S. Food and Drug Administration (FDA) to align on a registrational study design
with the goal to initiate a pivotal study in 2026. The Company currently has approximately 600 cryopreserved drug product bags of FT819 in inventory available for treatment of patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below are links to the Company Presentations at the 2025 ACR Convergence: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sunday, October&nbsp;26, 2025 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Poster Presentation |
Abstract #0663 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>iPSC-Derived, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Off-the-Shelf</FONT></FONT> anti-CD19 CAR T cells
Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Session Title: Systemic Lupus Erythematosus &#8211; Treatment
Poster I </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Session Time: 11:30AM &#8211; 1:30PM ET </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Monday, October&nbsp;27, 2025 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Poster Presentation |
Abstract #1270 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Increasing Participation in the FT819 Cell Therapy Trial Amongst People Living with Lupus: A Focus Group Study</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Session Title: Patient Outcomes, Preferences, &amp; Attitudes Poster II </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Session Time: 11:30AM &#8211; 1:30PM ET </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tuesday,
October&nbsp;28, 2025 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Poster Presentation | Abstract #2454 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-derived CAR <FONT STYLE="white-space:nowrap">T-cell</FONT>
Therapy</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Session Title: Systemic Lupus Erythematosus &#8211; Treatment Poster III </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Session Time: 11:30AM &#8211; 1:30PM ET </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Fate
Therapeutics&#8217; iPSC Product Platform </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal
and differentiation potential into all cell types of the body. The Company&#8217;s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master
cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in
composition, can be stored in inventory for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> availability, can be administered in combination with other therapies, and can potentially reach a broad
patient population. As a result, the Company&#8217;s platform is uniquely designed to overcome numerous limitations associated with patient- and donor-sourced cell therapies. Fate Therapeutics&#8217; iPSC product platform is supported by an
intellectual property portfolio of over 500 issued patents and 500 pending patent applications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About</B><B></B><B>&nbsp;Fate Therapeutics, Inc. </B>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fate Therapeutics&nbsp;is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived
cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf,</FONT></FONT> iPSC-derived cell products. The Company&#8217;s pipeline includes iPSC-derived <FONT STYLE="white-space:nowrap">T-cell</FONT> and natural killer (NK) cell
product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients.&nbsp;Fate Therapeutics&nbsp;is headquartered in&nbsp;San Diego,
CA.&nbsp;For more information, please visit&nbsp;www.fatetherapeutics.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 including statements
regarding the safety and therapeutic potential of the Company&#8217;s product candidates, including FT819, the Company&#8217;s progress, plans and timelines for the clinical investigation of its product candidates, including the Company&#8217;s
plans to complete <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and to submit IND applications for its product candidates, the initiation and continuation of enrollment in the Company&#8217;s clinical trials, the initiation of
additional clinical trials, including in new indications, and additional dose cohorts in ongoing clinical trials of the Company&#8217;s product candidates, the availability of data from the Company&#8217;s clinical trials and the Company&#8217;s
plans to provide updates on its clinical trials, the therapeutic and market potential of the Company&#8217;s research and development programs and product candidates, and the Company&#8217;s clinical and product development strategy. These and any
other forward-looking statements in this release are based on management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company&#8217;s product candidates, including those product candidates in clinical investigation, may
not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company&#8217;s product candidates, including preclinical
studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company&#8217;s product candidates or in the initiation and conduct
of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by
regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company&#8217;s product candidates are being developed, the amount and type of data to be
generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company&#8217;s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company&#8217;s product
candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during
preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any
of which could cause the Company&#8217;s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company&#8217;s periodic filings with the&nbsp;Securities and Exchange
Commission, including but not limited to the Company&#8217;s most recently filed periodic report, and from time to time in the Company&#8217;s press releases and other investor communications.&nbsp;Fate Therapeutics&nbsp;is providing the information
in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact:</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christina Tartaglia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision AQ </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">212.362.1200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">christina.tartaglia@precisionaq.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>fate-20251026.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/27/2025 10:43:14 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:fate="http://www.fatetherapeutics.com/20251026"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.fatetherapeutics.com/20251026"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fate-20251026_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fate-20251026_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>fate-20251026_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/27/2025 10:43:14 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>fate-20251026_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/27/2025 10:43:15 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fate-20251026.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FATE THERAPEUTICS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001434316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 26,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-1311552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12278 Scripps Summit Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">875-1800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FATE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d36426d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d36426d8k.htm">d36426d8k.htm</File>
    <File>fate-20251026.xsd</File>
    <File>fate-20251026_lab.xml</File>
    <File>fate-20251026_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d36426d8k.htm": {
   "nsprefix": "fate",
   "nsuri": "http://www.fatetherapeutics.com/20251026",
   "dts": {
    "inline": {
     "local": [
      "d36426d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "fate-20251026.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "fate-20251026_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fate-20251026_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-10-26_to_2025-10-26",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d36426d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-10-26_to_2025-10-26",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d36426d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.fatetherapeutics.com//20251026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-25-250674-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-250674-xbrl.zip
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M\)U>DP^&S %$(HP-.OG,X6#%G+B,"LJ'E.B4,7E1N!+P /D+,W'WW]!G(N=
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M=(-@$A"%3PMR&#SPA9#*OKMW_#K(P2% XW"CK9@7N*&#M"/-AO=$!/YC-.
M,3SU!9"O76+ .1-F=KR>;>B,.UQ+%1K0^Z2SLJ";99[*9?5T4T@*+9GG(QY7
MYG /\3 H(]NZ=1].@0%@.UR#0@!<WX(OVY6>%M-<5]"9(6B,6Y!V3&_L!9#+
M* /S'DH?,R@\M@2RZT+LYL,8'W!7MPEN9$;-)_JW(R;$Y1FP"@Q;VB!9A043
MKWB\8#)#3MS"/(5%29J2,.CCM@7]28C)(LL7@7F!0<]DLES;:@N)!L#*R$&J
M? #:.L!9I0( IY?__G$;K!?R4 ZBZPKD1CY0.'7).]2ELW>^+9GMDF6+JEOJ
MS"VCOF/OOJ^D;F(EU?H7DJ(9J >'5G _(].6"?$O,NV\8RPS^%?:Q-F &7+:
MN,/0_K_L(U5=@3,;!<)F::A.72/T/<+M$:T=4(X/00.27)L0T_#DM(2!:$?!
MM,I^'RE<>HL@_TW"J>N>]F8T!;YR/@BXV[250U&U*\8P"X8O&L:M 9@BC&VF
MB#)QOR\,>4%%6T$2*_[08V F@+-,:;T7-I0A!G&YG@_Y#0;K;JQ] 51?Q!KY
M-)_/&(L6\!9"F^!XO1<'DR/E.6SG0(M*V430%_:Q\&'R.5HPPLVA)X9=#UVK
M(0:XX.T\]#-">$YB%C0G+$V43PYQ#XLJ+_-<3<,;@8R%V<V&DBU(PPER?%(8
M>?N,#K\/2:H;SDKNUK%P8#_@IBV8J4D/ZME)50(W*9--"J4! D 9.T5,1'X#
MV1RZ]UQ>_0G^N(-[M^B)AUFF?;AG!2W#>Q7<TQ( 1LH(<:R6YHM5+ QV&DG#
M[B@6&K&(.@O&11G,#4P3(:!R<)RP33E)XQ$/X O+\;5TN<<!!$#'=DNEF/QT
M0<-%SQ(&_4!T=46_Z6,M>VC2+CLFN!N;CP).[:Q&NV6.Z?X+R0M@N!3A8VB7
MSMQ@"NEU]$)<>P.ZX:/_4B,:.5GP*N=0(C7*_?8$.%S\D0&7.ZQ*4YKQ+,H4
M:7@ZYVOG3B.#"J.?-6F"DDX#U !];';*$].<Q8//')7& O[2ECEDD>PRWS$,
MA 9$R[E;EU=GVQ5 7MW *E'&7SR4&G?QA2#0!L_ !FE]-R4'<TB+:*7/+N/B
M C!%!MR*C]-9B5"K($B\V*P93*9TQ5Y1H7P;'*!1H77&'N@?$U97GH#$NXP@
M>YI":FZ7 ,*#HH@SV>M3=(/T_Y[+()?C$<9(,>J2"2<J.E^TKIC!I>'I@NY,
MQN5U'3L>4F74<K5?:E7.#HL,F$=^2E[^P7S/M%,@^F.+^!\4UFVXQ5ATB_C.
MBTB4DR59=X=<TGWALE.[&=?CP)^^B.8QG-&W=7'35P=J5&AI3W-/7QWR\?0E
ME&'A6B*+P@V-^S@% H!W_YY!EUTUFKX*R';&C!\F+A).A1 1<)V$!S)U#!_Y
M<^KNQQW&"^(/8BQ$</T!!1Y<I%X0K%S4177!K1S7/0%>E'X2[LAH\7@[Y;T+
M@]]Z-A-<DIRFJH2/?>P'< ?D5CA:IM=NL(F "%;5BP&8"_M>96LMR,_<0C]G
M(;V* QO/"?@)% 1I@8UAL92*-6*^V :^.(C((_@23S:E1TZ#L7-T^(M4F$LX
MWX/>+EN\1W^7@0!<RJ=%^[GL3<0QC]:ET(/*P>#APM;NBL'63J#8AO:]9L;1
M,K!D3'3X^()IZV%<6=I?L<3]KW3Y2. [=+@WSG9F<+](2YB-("8#6ZB,K6<3
MF G?A=$<).H-T!DA',("'%PKHO='W(-M3\T^$5Z2G% VI"5N[;@X_"P\D@=&
M^8!>B T/,MOXRM.01$ @Q"EPTHW%J0YWS)1#;HYV@030WAA[0O64'LS7]F.Q
M,P_C'FJRSB'HY9,EE0WG( UJJWHDP1S0@,[31%.&9?(E,X/E3.4D%?(HV<*I
MT)SR;,;RQ.3SA$KTDG=RS(9+A*0XN^=:"@L3( <VZ#RR%76KIMJY-Z(,J0&9
M@=E2$0EM]&7:%H.-N-1#%;A$A90)DXH<L!N6J8!RR*&<&Z/,7#VFB&BE@D%$
M\XT'+6E"=NU[15FBD^@*G*=C'";I!*"&6,)IH<1X)%(,!38&<W>5#NB1\WNH
M!%I'Y/%G&N"$%B:B-+EEB+S.%+#K'+2:V$N2X^!*3X&ST_H_I?N:Z+;UK2MR
MKI?7NDC0VG"9]0!VQK0),.7O0&_XC*TA+*19OS,LIP';!: D!J9=A:+/W:*Z
M"V$YS4Z]D6_9LX*M;6>H,S/A.5:7! 1[:Q(@=T&Q>M)22E9O0R[1'(<9"/6S
MF4'<]3 T7I Q^])X,:$G5%G[X)QP:4FV3="8=43LI"T&4TY<AS6G/ "8I2!S
M 4$N[CNL9;V\?4O0?!!GA$BY.2O4^P(^!EE?!8VETFW@J"T!,%FU3VYM!+M-
MRR2RU];FPQDBB4D4,7.XH3(1U2"&44!U#ECHG9!@?]+"LMOR Y)PZ@G_SIM
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MYY6<@OX!NV,PD 1 Z:4QX'\C("%Y:L2% '<3V3((N+G.$+L@0I/)9 <L_S"
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M#->=Z#_?FN3B\Y>2G_X(W?[51E*VWR7M/["V =$W/D_0TR:IVC"[1Q&K]VF
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MU:8F$P>M#HF\^YZFE7ZW=C0-FG8#=2I]\WG;Z\UBAK6WX(^2.D+4WCI:+KK
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MPZ&:VN%ZR^GT6%@[HOI2VC'J\+2]P;,>9GWL@:)\@)/5\A=8G79.[8GKB^N
M88?MS!ML[AHPPC0>2ZNLJ2^DLD_'YH-W;)X O>(E.KW&J_RID';$]:>U8]AA
MN_ &F[N72J3*I2IR^XPIAKZ<XW2QZLOTQ'N-?PA57Z1'V7> ?_0,\"WC\##/
MQJ!.H[FMJSNZ;:^.TZ5GG$9T.4@Q#6S"UH^I;X%V,$C="1XTOL'9;GJ&LY>F
MF&2]V>"3,L2GH:P,4'>,E:8=PMA/A'W<?50CN1!O K@M]P3?MF4'SY\'\%)7
MBNOXHWI2\H79-<2W$-R+X0G&/=^.I6]/ZYO^/$EM*/^#Y:??FE9'\(3CCFM'
MT9^'=SN?]!304[B5-?4E5?;IV)Q[P\;^*<*?9E*<^)"PKZLOHWVOCI,_BRR_
MH3\#HB^S;"XV]\CZ6%@'Q/4E=L"PP^;/(LNSY"QAAHGI/5Z,%;/6CF-6I:PO
ML"JWCI8_*R9/"NR0 [Q;*A9D[9^9ZG$R.7Y:?"U"?>F]YMI1]&<]9:<W ZWG
MH/X]RXHXWA"M\+[A>N;/PLHS)'-K,6Z-1\SPHV\E]W7UY;;OU7'R9_5DI*A]
MZ^IYE8WET9>['5%]">T8=7C\61]Q0^QFF<RHF,(I+Y54:^L+J]JO8^;;.LA-
M!FJ*8^]G)1=FAO-[3L6)[RX<"%%?@J_:=B#_AZ60JV@O-7=88-^B7!^Q7_:=
M0"SY"U!+ 0(4 Q0    (  8X6UL-+E85#1H  "*)   -              "
M 0    !D,S8T,C9D.&LN:'1M4$L! A0#%     @ !CA;6T39EH\<'   4G@
M !               ( !.!H  &0S-C0R-F1E>#DY,2YH=&U02P$"% ,4
M"  &.%M;TOG7?T$#  !D"P  $0              @ &"-@  9F%T92TR,#(U
M,3 R-BYX<V102P$"% ,4    "  &.%M;'<NI\&$&  "^0P  %0
M    @ 'R.0  9F%T92TR,#(U,3 R-E]L86(N>&UL4$L! A0#%     @ !CA;
M6X )=4"Z!   C"H  !4              ( !AD   &9A=&4M,C R-3$P,C9?
=<')E+GAM;%!+!08     !0 % #X!  !S10     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d36426d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fate-20251026.xsd" xlink:type="simple"/>
    <context id="duration_2025-10-26_to_2025-10-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <startDate>2025-10-26</startDate>
            <endDate>2025-10-26</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2025-10-26_to_2025-10-26"
      id="Hidden_dei_EntityRegistrantName">FATE THERAPEUTICS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-289">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-10-26_to_2025-10-26"
      id="Hidden_dei_EntityCentralIndexKey">0001434316</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-300">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-301">2025-10-26</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-302">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-303">001-36076</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-304">65-1311552</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-305">12278 Scripps Summit Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-306">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-307">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-308">92131</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-309">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-310">875-1800</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-311">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-312">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-313">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-314">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-315">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-316">FATE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-317">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-10-26_to_2025-10-26" id="ixv-318">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
